Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Aerie Pharmaceuticals
Enrollment will be stratified according to subject's IOP-lowering medical therapy regimen as follows: * Latanoprost monotherapy (Latanoprost Mono) * Latanoprost plus 1 additional IOP-lowering agent (Latanoprost +1) * Latanoprost plus 2 additional IOP-lowering agents (Latanoprost +2) Aerie Pharmaceuticals was acquired by Alcon Research LLC on November 22, 2022.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted